Thursday 3rd December 2020 |
Text too small? |
The United Nations (UN) has approved the recommendation from the World Health Organization (WHO) to remove cannabis and cannabis resin from Schedule IV of the 1961 Single Convention on Narcotic drugs, where it sat alongside Heroin and other narcotics.
What does this mean for the medicinal cannabis sector worldwide, in New Zealand, and for Cannasouth?
Removing cannabis from Schedule IV means the medicinal use of cannabis is no longer a scheduled narcotic. Notwithstanding that cannabis remains a controlled substance in Schedule I. This may lead to member nations of UN re-evaluating cannabis classification and legislation to adopt the new UN scheduling.
Regulatory Affairs Specialist, Lina Lozano says, “New Zealand is ahead of the curve, with the introduction the Medicinal Cannabis scheme in April this year. This UN vote may encourage other countries to adopt similar legislation that could create future export opportunities for New Zealand medicinal cannabis products. However, it is important to note that Schedule 1 does require high levels of international control.”
Chief Science Officer, David Gill says, “This is a very positive move forward and would lead to significantly more clinical research and investment. This could unlock the full potential of this unique plant and further development of new and effective medicines.
“Cannasouth’s business model has always been focused on the medicinal cannabis market, and this outcome further supports our belief in the therapeutic benefits of cannabis as a medicine.”
See the link below for more details:
2020-12-03 UN Vote to Reschedule Cannabis
No comments yet
Infratil releases Climate Related Disclosures
The Warehouse Group Appoints Chief Digital & Transformation
The Financial Collapse Has Already Begun - Will You Be Caught Off Guard?
NWF - IMPLEMENTATION OF SCHEME OF ARRANGEMENT
EROAD Publishes FY25 Group Climate Statement
Synlait provides performance update
Air New Zealand Chief Executive Officer Appointment
July 30th Morning Report
IKE 1Q FY26 Performance Update
July 29th Morning Report